Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo by Andersson, Y et al.
Synergistic anti-cancer effects of immunotoxin and cyclosporin
in vitro and in vivo
Y Andersson*,1, O Engebraaten
1,2 and Ø Fodstad
1,2
1Department of Tumor Biology, Institute for Cancer Research, Norwegian Radium Hospital, Rikshospitalet University Hospital, Oslo N-0310, Norway;
2Faculty Division, The Norwegian Radium Hospital, University in Oslo, Oslo N-0310, Norway
BACKGROUND: The clinical use of immunotoxins (ITs) has been hampered by hepatotoxicity, and the induction of a strong human-anti-
IT response. The human-anti-IT response results in neutralisation of the immunoconjugates, rendering repetitive treatment
inefficacious.
METHODS: We evaluated the combination of cyclosporin A (CsA) with various Pseudomonas exotoxin A-based ITs in human breast,
cervical, and prostate cancer cell lines measured by protein synthesis, cell viability, and TUNEL assay. Furthermore, expression of
essential proteins were analysed by western blot. We used cervical cancer model in nude rats to evaluate the anti-metastatic effect of
the combination. The anti-immunogenic response by the CsA treatment was investigated in immunocompetent rats.
RESULTS: The combination of CsA with ITs caused remarkable synergistic cytotoxicity, in several cancer cell lines, characterised
by protein synthesis inhibition, decreased cell viability, and an increased apoptotic index. Furthermore, the combination strongly
inhibited formation of metastases in a cervical cancer model in nude rats with a statistically significant increase in median survival
time of the combination-treated animals, as compared with those receiving a suboptimal dose of IT alone. Notably, we found
in immunocompetent rats that the anti-IT immunoresponse elicited by repeated administration of IT was efficiently abrogated by
CsA; notably the antibody responds towards the highly immunogenic PE was shown to be prevented.
CONCLUSION: The combination of ITs and CsA might constitute a significant improvement in the clinical potential of systemic
IT treatment of cancer patients.
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Immunotoxins (ITs) represent a promising group of targeted
therapeutics for cancer patients in which standard treatment is
no longer an option. ITs are dimeric proteins consisting of a
targeting moiety (often an antibody) covalently linked to a toxin
(Ricin, Pseudomonas exotoxin A (PE), Diphtheria toxin), which
by inducing arrest of protein synthesis and induction of apoptosis
result in subsequent cell death (Kreitman, 2003). The targeting
moiety binds to antigens expressed on cancer cells, theoretically
leaving normal cells unaffected.
We have shown earlier that the 425.3PE and BM7PE increased
symptom-free survival in human breast and cervical cancer models
in nude rats (Engebraaten et al, 2000). These ITs consist, respec-
tively, of the 425.3 (anti-EGFr) and the BM7 (anti-mucin-1) intact
murine monoclonal antibody, covalently linked to the bacterial
toxin PE.
The clinical use of ITs has been hampered by hepato-
toxicity, neurotoxicity, vascular leak syndrome (VLS), and the
induction of a strong human-anti-mouse-antibody (HAMA)
response. The HAMA response, or more precisely the anti-IT anti-
body response, results in neutralisation of the immunoconjugate,
rendering the treatment inefficacious, thus limiting the efficacy
of repeated administration of the treatment. Such repeated
IT administration might be needed for an efficient anti-cancer
effect of IT.
Cyclosporin A (CsA) is a cyclic undecapeptide, routinely
used in autoimmune disorders and organ transplantations. The
CsA molecule is able to bind to both cyclophilin and calcineurin.
The cyclophilins are important in protein folding, cytoplasmic
trafficking of proteins, and in import of newly synthesised proteins
to the mitochondria, and CsA might impede these effects by
binding to cyclophilins. Calcineurin, a Ca
2þ- and calmodulin-
dependent phosphatase, is a critical component of the immuno-
suppression pathway by transcriptionally blocking many genes
involved in the establishment of the immune response of
T lymphocytes and by binding to the CsA–cyclophilin complex
(Clipstone and Crabtree, 1992). CsA has been demonstrated
in vitro to be either a pro-apoptotic or an anti-apoptotic agent,
depending mainly on the cell type studied and on the CsA
concentration used.
Here, we document that CsA abrogates the IT-evoked, anti-IT
antibody response in immunocompetent animals and hence
should allow repeated administration of effective IT doses in the
clinic. In parallel, the combination exerted strong synergistic
effects in vitro, and in a nude rat model for cervical cancer it
significantly inhibited the formation of metastases.
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sMATERIAL AND METHODS
Material
The anti-EGF receptor antibody 425.3 was a gift from Dr R Reisfeld
(Scripps Institute, La Jolla, CA, USA) (Mueller et al, 1991). The
MOC31 antibody (MCA Development, Groningen, the Netherlands)
detects the epithelial glycoprotein EGP-2. The BM7 antibody, which
recognises a glycosylated epitope on the MUC1 mucin, was kindly
provided by Dr S Kaul (Frauenklinik, Heidelberg, Germany). The
antibody was conjugated to PE (obtained from Dr Darrel Galloway
(University of Ohio, Columbus, OH, USA) by a thioether bond
formed with the reagent sulfo-SMCC (sulfo-succinimidyl-4-(N-
maleimidomethyl) cyclohexane-1-carboxylate) (Pierce, Rockford,
IL, USA) as described earlier (Godal et al, 1992).
CsA for in vitro use was purchased from Calbiochem (San
Diego, CA, USA) and was resuspended in dimethyl sulfoxide
(Sigma Chemical Co, St Louis, MO, USA). Sandimmun neoral
(CsA) for in vivo administration was from Novartis (Oslo, Norge).
Sirolimus, tacrolimus, and cycloheximide (CHX) from Sigma
Chemical. Ricin was a kind gift from Sjur Olsnes (Department of
Biochemistry, Institute for Cancer Research, in our institution).
Cell culture
Establishment and characterisation of the MA11 breast cancer cell
line has been described earlier (Rye et al, 1996; Micci et al, 2001).
The MT-1 cell line was originally obtained (Engebraaten et al,
2000), but has recently been determined to be a variant HeLa cell
line, thereafter named HeLa*. The prostate cancer cell line DU-145
was purchased from American Type Tissue Culture Collection
(ATCC, Rockville, MD, USA). The cell lines were grown in
RPMI 1640 medium supplemented with 10% heat inactivated fetal
calf serum (FCS) and glutamax (Life Technologies, Paisley, UK)
and kept in a standard tissue culture incubator at 371C. The
glioblastoma cell lines U-87MG (obtained from ATCC), U-251MG,
and D-54MG were grown as recently described (Hjortland et al,
2003). Confluent cells were detached with 0.01 M EDTA. For inject-
ing into the animals, cells in exponential growth phase were used.
Measurement of protein synthesis inhibition
Protein synthesis inhibition caused by IT or the protein synthesis
inhibitors CHX and ricin were measured by using the [
3H]-leucine
incorporation assay (Sandvig and Olsnes, 1982). Cells (4 10
4 per
well) were seeded in 48-well plates and allowed to grow overnight
before addition of different concentrations of IT. After 20h incubation,
the cells were washed twice with cold phosphate-buffered saline (PBS),
0.1% FCS, and incubated with [
3H]-leucine (2mCiml
 1) in leucine-free
medium for 45min at 371C. The cells were then washed with 5%
trichloroacetic acid for 10 and 5min, respectively, and dissolved in
0.1 M KOH for at least 5min. The resultant solution was transferred to
the liquid scintillator Aquasafe 300 Plus (Zinsser Analytic, Frankfurt/
Main, Germany). Sample counts were determined in a liquid
scintillation counter (LKB Wallac, Perkin Elmer, Boston, MA, USA).
Assays were performed in duplicate, and repeated at least three times.
CsA was added 1h before the IT. Serum (0, 0.025, 0.25, or 2.5%) was
added just before addition of IT.
Evaluation of the effect of IT on cancer cell viability
The IT effect on cell viability was measured using the CellTiter 96
Aqueous One Solution (MTS-assay) (Promega, Madison, WI,
USA). Cells were seeded in 96-well plates at 3000–8000cells/well
and grown to about 40–80% confluence (depending on incubation
time with IT), and the old medium was replaced with new medium
containing IT and incubated at 371C for 24h–6 days. CsA,
tacrolimus, and sirolimus were added 1h before the IT. Serum
(0, 0.025, 0.25, or 2.5%) was added just before addition of IT.
The CellTiter 96 Aqueous One Solution was then added to the
wells, and the absorbance was measured 2–4h later at a wave-
length of 490nm. The values for total viability of the treated cells
were compared with the values generated for the untreated control
cells and reported as the percentage cell viability. The assays were
performed in triplicate, and repeated at least three times.
The results from the cell viability assay were analysed by use of
CalcuSyn (version 1.1 Biosoft, Cambridge, UK), a commercially
available software package, a program based on the method of
Chou and Talalay (1984), which performs single and multiple
drug dose–effect calculations and determines the presence of
antagonism, additivity, or synergism between treatment groups
on the effect of the growth inhibition caused by the drugs alone
relative to the effect produced by the combination. The program
returns combination index (CI) values; values o 0.9 indicate
synergy, values between 0.9 and 1.1 indicate additive effects, and
values 41.1 indicate antagonistic interactions.
Western blot analysis
After IT incubation for the indicated time period, both adherent
and floating cells were lysed by an SDS-boiling method. Cell pellets
were resuspended in the lysate buffer (2% SDS, 1mM Na3VO4,
and 10mM Tris–Cl (pH 7.6)), which was held at 1001C when
added, and the lysates were boiled for 5min. After six passages
through a 20 G-gauge syringe on ice, the lysates were cleared
by centrifugation. Protein concentrations were then determined
using the BCA protein assay (Pierce). The lysates were snap frozen
in liquid N2 and kept at  701C.
A portion (20mg of protein) of each lysate was fractionated by
8–12% SDS–polyacrylamide gel electrophoresis and transferred to
polyvinylidene difluoride membrane (Bio-Rad, Hercules, CA, USA)
by electroblotting. The filters were probed with a designated
primary antibody. The anti-caspase-3 was purchased from R&D
System (Minneapolis, MN, USA) and the anti-a-tubulin from
Oncogene Research Products (San Diego, CA, USA). The anti-
PARP antibody was purchased from Roche Diagnostics (Man-
nheim, Germany) and the anti-Mcl-1 antibody from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Immune complexes were
detected with appropriate HRP-coupled secondary antibodies.
Peroxidase activity was visualised with enzyme-linked chemilumi-
nescence (Amersham Pharmacia Biotech, Buckinghamshire, UK)
and quantified by densitometry (Imagemaster, Amersham
Pharmacia Biotech). All western blots were stained with amido-
black and probed with anti-a-tubulin to confirm equal loading and
transfer of samples.
TUNEL staining for flow cytometry
DNA fragmentation was quantified by terminal deoxynucleotidyl
transferase-mediated dUTP-biotin nick end labelling (TUNEL). After
IT incubation for the indicated time period, both adherent and
floating cells were collected, washed in PBS, and fixed in
100% methanol and stored at  201C. The terminal transferase assay
kit (Boehringer, Mannheim, Germany) was used as described earlier
(Lund et al, 2005) to detect free 30-OH ends of cleaved DNA.
Fragmented cells and debris were excluded from measurements by
gating the remaining intact cells in a forward and side scatter
analysis. The FACStar flow cytometer (Becton Dickinson, San Jose,
CA, USA) was set up to measure forward and side scatter and FITC
fluorescence (520–550nm). FACS analysis was carried out on
1 10
4 cells. The CsA was added to the cells 1h before addition of
IT at a final concentration (0.2–2mM)a si n d i c a t e d .
Animals
All procedures and experiments that involved animals were
approved by The National Animal Research Authority and carried
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Vertebrates used for Scientific Purposes. Nude rats (Han: rnu/rnu
Rowett) and immunocompetent rats (Rowett nu/þ) were bred in
our rodent facility. Animals were kept in a specific pathogen-free
environment, in positive pressure rooms with filtered and
humidified air. The animals were kept under standard conditions
and fed with standard pellets and fresh water.
Tumour cell inoculation: experimental endpoints
Four- to five-week-old nude rats of both sexes were used. Rats
injected with cells in the left cardiac ventricle (LV) were
anaesthetised by s.c. injection of a mixture containing 0.1mgkg
 1
fentanyl, 5mgkg
 1 fluanison, and 2.5mgkg
 1 midazolam. Briefly,
a microinfusion set containing a 27-gauge needle connected to
an infusion tube was used. The needle was inserted through the
third intercostals space into the LV of the heart after a midline
skin incision. When, on aspiration, light red pulsating blood was
observed in the tube, 0.2ml of cell suspension containing 10
6
HeLa* cells or 2.5 10
6 MA11 cells were injected into the ventricle,
the needle withdrawn, and the skin closed with staples. The
sandimmun treatment was performed in animals anaesthetised
with halothane and N2O mixed with O2 and was administered
approximately 6h after cancer cell injection and thereafter
everyday for a total of 5 days. The IT treatment was administered
after 24h diluted to a 100ml volume. The animals were then
inspected daily with respect to symptoms of tumour-related
disease and general condition. A total of 54 animals and 45
animals were injected with cancer cells, HeLa*, and MA11 cells,
respectively. The animals were divided into four groups: control,
IT, ITþCsA, and CsA alone, at least 10 animals were included per
group. The animals were killed when symptoms of metastatic
disease appeared. As described previously, disease related to
growth of HeLa* or MA11-derived metastases caused neurological
symptoms, cachexia, and weight loss (Engebraaten et al, 2000).
The time from inoculation of the tumour cells to the appearance of
symptoms of metastasis was recorded as the mean latency time.
The Kaplan–Meier plot estimated the survival function from the
life-time data. The log-rank test was used to assess the significance
of observed differences in survival times between the different
treatment and control groups.
Anti-IgG IT in immunocompetent rats
Immunocompetent rats (Rowett nu/þ) weighing approximately
400–500g were used in this study. The animals were kept under
standard conditions and fed with standard pellets and fresh water.
The rats were divided into four groups: control (n¼7), IT (n¼10),
ITþCsA (n¼10), and CsA (n¼7). The treatment schedule of the
immunocompetent rats started at day 0 with CsA (10mgkg
 1 per
day for 5 days) injected intravenously (i.v.) and then every day for
a total of 5 days in a volume of 100ml, in the CsA-treated animals.
The control group received PBS at day 0 and then every day for a
total of 5 days in a volume of 100ml. A single i.v. injection of
MOC31PE (100mgkg
 1) was given at day 1 to the two groups, IT
and ITþCsA. The treatment schedule was repeated every second
week for a total of 8 weeks. Blood samples were collected at day 0
before the start of the experiment and then every second week. The
physical condition of the animals was regularly monitored. No
toxicity was seen when monitoring animals for loss of body weight
and decline in general condition. Blood was drawn from the rats
and allowed to clot overnight at 41C. The blood was then
centrifuged at 2800r.p.m. for 10min at 41C and the serum layer
was removed, aliquoted, and stored in at 41C. Ninety-six-well
Costar ELISA plates were coated with MOC31PE and analysed for
anti-IgG IT. The anti-IT IgG was measured by ELISA and plotted
against a standard curve.
RESULTS
CsA synergistically increases the IT-mediated cell death in
MA11 human breast cancer cells
The concentration-dependent efficacy of the combination of
425.3PE and CsA on protein synthesis was examined in MA11
breast cancer cells. The IC50 value for inhibition of protein
synthesis was 1ngml
 1 of 425.3PE alone compared with approxi-
mately 0.1ngml
 1 of 425.3PE combined with CsA (2mM)
(Figure 1A), whereas CsA alone only gave a marginal effect. These
results were supported by the findings that the combination with
CsA (2mM) effectively increased the anti-cancer effect of 425.3PE
(1ngml
 1) measured in the MTS assay. Thus, after 24h the cell
viability decreased by more than 50%, from 38% to 17%, compared
with untreated cells (Figure 1B), whereas CsA alone had no effect.
In the concentrations used, neither the PE toxin nor the 425.3
antibody alone, or in combination with CsA, had any effects on
protein synthesis and cell viability (not shown), showing that the
synergistic cytotoxicity of IT and CsA is a specific event.
We have shown earlier that our PE-based ITs induce apoptosis
in several types of cancer cells (Andersson et al, 2004, 2006).
Hence, the synergistic effect of the IT and CsA combination could
conceivably be mediated through induction of apoptosis. Western
blot analysis showed an efficient cleavage of PARP (poly (ADP-
ribose) polymerase) to the 85kDa inactive fragment in MA11 cells
treated with 425.3PE (1ngml
 1)þCsA (2mM) for 5h compared
with the cells treated with 425.3PE only (Figure 1C). CsA alone had
no influence on PARP inactivation. In the MA11 breast cancer cells
treated with a sub-toxic dose of 425.3PE (0.1ngml
 1) for 4 days
with or without CsA (2mM) (Figure 1D), the apoptotic index after
treatment was measured by TUNEL analysis. In the combination-
treated cells, the apoptotic index was 25% compared with 5% in
the IT-only treated cells, 10% in CsA-treated cells, and 3% in
untreated cells. The observation suggests that induction of
apoptosis may be the major contributing factor to the synergistic
anti-cancer properties of the combination therapy.
Strong synergistic effects of the IT and CsA combination in
cancer cells of different origins
The potential of the combination treatment of ITþCsA was
further investigated in several different cancer cell lines (cervical;
HeLa*, prostate; DU145 and glioblastomas; U87MG and D54MG
(data not shown)), and also using different ITs (BM7PE,
MOC31PE, and 425.3PE).
HeLa* cells were incubated with increasing doses of BM7PE
(0.01–100ngml
 1) alone and with increasing concentration of
CsA (0.2–2mM) for 6 days (data shown only for 2mM of CsA)
(Figure 2A). The rationale to use HeLa* cells and BM7PE in this
study was the results in our previous work in the HeLa* metastasis
model, in which the BM7PE alone showed only a limited anti-
metastatic effect (Engebraaten et al, 2000). Our objective was to
examine if the combination therapy could improve the anti-
metastatic effect of BM7PE. In vitro the cell viability of HeLa*
decreased with increasing doses BM7PE alone and when combined
with CsA the increase in cell death was synergistically enhanced,
resulted in approximately 40-fold lower IC50 compared with IT
monotherapy (Figure 2A). Very low BM7PE doses alone, equal to
or less than 1ngml
 1, resulted in slightly increased cell viability,
suggesting induction of pro-survival signals at these concentration
level (Andersson et al, 2006). However, even at these low IT doses
(BM7PE p1ngml
 1) we found that, the combination resulted in
a synergistic increase in cell kill; IT (1ngml
 1) plus CsA (2mM)
decreased the cell survival by 40% compared with IT alone (114%),
whereas CsA (2mM) mono-treatment showed no effect.
The Calcusyn program was used to calculate the CI values for
BM7PE (0.01, 0.1, 1.0, 10, and 100ngml
 1) plus CsA (0.2, 0.4, 0.8,
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considered ‘strongly synergistic’, and ‘synergistic’ ranges lie
between 0.3 and 0.7 units. Synergistic or strongly synergistic
effects (CI values between 0.1 and 0.7 units) were obtained with
10 and 100ngml
 1 of IT in combination with CsA (0.4, 0.8, and
1.6mM) (Figure 2B). The combination was determined to be
antagonistic at the lowest IT concentrations (0.01–1ngml
 1),
independent of CsA concentrations with CI values over 1 (data
not shown). Thus, IT and CsA interact synergistically only at
concentrations where IT alone caused cell death. ‘High’ concen-
trations of CsA alone, 0.8, 1.6, and 2 M, gave up to more than 40%
reduction in cell viability in HeLa* cells (data not shown), whereas
lower CsA concentrations (0.2 and 0.4mM) resulted only in a minor
effect on cell viability on 6 days of treatment.
HeLa*cells treated with BM7PEþCsA (1ngml
 1þ2mM) were
analysed for TUNEL-positive cells (Figure 2C) and the results
showed that the observed synergistic effect in cell viability was
at least in part because of an increase in apoptotic cells. Thus,
after 6 days of treatment HeLa* cells showed 4% (IT) and 24%
(combination) positive cells compared with 3% for untreated cells
and 12% for CsA-only treated cells.
DU145 prostate cancer cells were treated with MOC31PE (0.1,
1.0, 10, and 100ngml
 1) with or without CsA (2mM) (Figure 2D).
The IT (10ngml
 1)þCsA combination decreased the cell viability
by 60% compared with 20% by IT (10ngml
 1) and 10% by CsA
alone, all compared with untreated control cells. Compared with
the other cell lines, U87MG glioblastoma cells were less sensitive
to the CsA treatment. Thus, the CsA concentration had to be
increased to achieve a synergistic combination-induced cell
death (Figure 2E). In these cells, the combination of 425.3PE
(0.1ngml
 1) and CsA (4mM) caused a synergistic decrease in cell
viability (70% cell kill), IT alone 20%, whereas CsA alone had only
a minor effect on cell viability. Similar results were obtained for the
glioblastoma cell line D54MG (data not shown).
The immunosuppressors tacrolimus and sirolimus had no
beneficial effect on IT-induced cell death
Two widely used immunosuppressors, tacrolimus (FK-506) and
sirolimus (rapamycin), were tested in combination with IT. HeLa*
cells were incubated with BM7PE (10ngml
 1) in combination with
either CsA (2mM), tacrolimus (2mM), or sirolimus (2mM) for 3 days
before the MTS assay was performed. Interestingly, the immuno-
suppressors tacrolimus and sirolimus (0.2–8mM) did not influence
the IT-induced cell death, in contrast to the benefits of the
synergistic effect observed with CsA (Figure 3). Furthermore, the
immunosuppressors did not affect the IT-induced cell death even
at concentration up to 8mM (data not shown). No synergism was
observed with tacrolimus and sirolimus when the same experi-
ments were performed with MA11 and glioblastoma D54MG cells,
but sirolimus was by itself highly cytotoxic to MA11 cells (data
not shown). The data suggest that the synergistic CsA-mediated
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Figure 1 CsA enhanced the cytotoxicity of the 425.3PE immunotoxin in MA11 breast cancer cells. (A) Cells were incubated with different
concentrations of 425.3PE and/or a fixed dose of CsA (2mM) for 20h. The rate of protein synthesis in each cell culture was expressed as a percentage of the
value obtained in untreated control cells. The data are expressed as the mean of triplicates, representative of two independent experiments. (B) Cells were
incubated with 1ngml
 1 IT 425.3PE and/or CsA (2mM) for 20h before the MTS assay was performed. The results represent the means of four
determinations and the assay was repeated at least three times. (C) After treatment with 425.3PE and/ or a dose of CsA (2mM) for 5h, MA11 cell lysates
were subjected to western blotting. The filters were incubated with anti-PARP antibody as described in Material and Methods. The gels represent at least
three independent experiments. Anti-a-tubulin detection was used to confirm equal loading of proteins (data not shown). (D) MA11 cells exposed to
425.3PE (0.1ngml
 1) for 4 days and pretreated or not with CsA added 1h before the IT at a final concentration of 2mM. The numbers represent percentage
of apoptotic cells detected by TUNEL staining of treated and untreated cells analysed by flow cytometry. The experiments were performed twice.
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sIT-induced reduction in cell viability is most likely unrelated to the
mechanisms that CsA, tacrolimus, and sirolimus have in common
by selectively blocking transcriptional activation of defence-related
genes early in the T-cell signal transduction pathway. However, the
difference might be explained by the fact that the drugs have
different cellular targets.
Combination induced increased animal survival in
metastasis models in nude rats
The observed advantageous in vitro effects of the combination of
IT and CsA were tested in two of our previously reported human
tumour models in immunodeficient rats, simulating micrometa-
static disease. The rats were injected with either HeLa* cells or
MA11 cells in the LV, and 6h later the animals were treated i.v.
with 10mg per day of CsA daily for 5 days. BM7PE was given i.v.
on day 1 after HeLa* cell injection as a single bolus (10mg per 60g
animal) and MOC31PE (10mg per 60g animal) was given i.v. on
day 1 after MA11 cells injection. In untreated animals, the meta-
static disease caused debilitating symptoms. In the cervical tumour
model, the combination (n¼15) was more effective in inhibiting
the development of metastasis compared with IT monotherapy
(n¼13), as demonstrated in two independent experiments
(four treatment groups, total 13–15 animals/treatment group)
(Figure 4A). Notably, a statistically significant prolongation in
survival (P¼0.022) was found (Figure 4B), as calculated by the
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Figure 3 Tacrolimus or sirolimus had no additive or synergistic effect
on IT-induced cell death. The cervical cancer cell line HeLa* cells were
incubated with a fix dose of BM7PE (10ngml
 1) and/or a dose (2mM)
of CsA, tacrolimus, and sirolimus for 3 days before the MTS assay
was performed. The data are expressed as the mean of triplicates,
representative of two independent experiments.
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Figure 2 CsA synergistically enhanced the IT effect in several types of cancer cells (A) HeLa* cells were incubated with different concentrations of the
BM7PE IT and/or a dose of CsA (2mM) for 6 days before the MTS assay was performed. (B) The table shows the calculated combination index (CI)
determined by Calcusyn software (version 1.1, Biosoft). Data are expressed as the mean of triplicates, representative of two independent experiments. (C)
HeLa* cells exposed to BM7PE (1ngml
 1) for 6 days and pretreated or not with CsA added 1h before the IT at a final concentration of 2mM. The numbers
represent percentage of apoptotic cells detected by TUNEL staining of treated and untreated cells analysed by flow cytometry. The experiments were
performed twice. (D) DU145 prostate cancer cells were incubated with different concentrations of the MOC31PE as indicated in the figure and/or a dose of
CsA2 (2mM) for 3 days before the MTS assay was performed. The data are expressed as the mean of triplicates, representative of two independent
experiments. (E) U87MG glioblastoma cells were incubated with different concentrations of 425.3PE as indicated in the figure and/or a dose of CsA2 (2mM)
or CsA4 (4mM) for 3 days before the MTS assay was performed. The data are expressed as the mean of triplicates, representative of two independent
experiments.
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sAll Pairwise Multiple Comparison Procedures using the Holm–
Sidak method. No toxicity was observed with this CsA dose or even
by the double dose of CsA (20mg per day) in combination with IT
(10mg per 60g animal). The same experimental setting was used
for a breast cancer model (MA11 cells) in rats treated with the
MOC31PE. A trend towards a positive effect of the combination
was obtained, but statistical significance was not reached because
of one long-term survival in the IT group (n¼10). The mean
latency in days was nearly the same for the IT and the ITþCsA
group, 56–58 days. Importantly, the surviving fraction of rats in
the combination group was higher compared with IT mono-
therapy group; in the IT group 1 out of 10 rats survived more than
90 days compared with 4 out of 12 rats in the combination group.
However, the CsA alone had no significant inhibitory effect on
metastasis and none of the agents alone or in combination caused
any weight loss.
CsA prevented antibody immune response against IT
in vivo
The possibility that CsA could inhibit IT-induced antibody
response was studied in immunocompetent rats. The animals
were treated with CsA, 10mgkg
 1 per day one to five, with bolus
injections of IT (100mgkg
 1) given at day 2 in the 2-weeks cycle. A
total of four treatment cycles were given. Serum from IT-treated
animals was analysed for anti-IT antibodies in an ELISA assay.
Two weeks after the second injection of IT, anti-IT IgG was already
highly elevated (1384±1744mgl
 1) in IT-treated animals (n¼10)
(Figure 5A). During the sequential administration of IT the anti-IT
levels continued to increase dramatically, and 2 weeks after the
fourth injection of IT (n¼10) the mean total anti-IT antibody
levels had reached 20810±17328mgl
 1, after a treatment period
of 8 weeks. Notably, no anti-IT antibodies were detected in the
combination-treated group (ITþCsA, n¼10) with mean plasma
anti-IT level close to the background (10±12mgl
 1). The plasma
anti-IT IgG in control mice (untreated or CsA alone, n¼7 per
group) was undetectable, as expected. None of the agents alone or
in combination caused any weight loss.
The specificity of the induced antibody response was examined
in U251MG glioblastoma cells, which has a high expression of the
a-macroglobulin receptor (Hussaini et al, 1999), which is the
receptor protein to which the PE binds. Serum from IT-treated
immunocompetent animals was analysed for the presence of
neutralising anti-IT-antibodies on PE-induced cytotoxicity in the
MTS assay (Figure 5B) and on PE-induced inhibition of protein
synthesis (
3H-leucine incorporation assay) (Figure 5C). In
U251MG cells treated for 24h with PE alone (1000ngml
 1) caused
a more than 60% reduction in cell viability, which was almost
completely blocked by the addition of serum (2.5%) from the
animal group that had been repeatedly (four times) treated with IT.
This observation suggests that the anti-IT antibody response is
not only evoked by the murine monoclonal antibody part of the IT
but also by the PE moiety. Importantly, when serum from animals
treated with the ITþCsA combination was used, no inhibition of
PE-induced cell death was seen. Fetal calf serum as well as serum
from the vehicle-treated and CsA-treated control groups had no
effect on PE-induced cytotoxicity in U251MG cells (Figure 5B). The
PE-induced inhibition of protein synthesis was also demonstrated
in U251MG cells (Figure 5C). PE alone (1000ngml
 1) decreased
protein synthesis to 30% of untreated control levels, whereas the
addition of serum (2.5% and 0.25%) from IT-treated animals
completely hindered the PE-induced inhibition of protein synth-
esis (0.025% serum had no effect).To exclude the possibility that
components involved in protein synthesis could be unspecifically
inhibited by the rat serum, U251MG glioblastoma cells were
incubated with ricin (1mM) and CHX (5mgml
 1) in the presence
and absence of IT-treated animal serum (2.5%) for 24h before
measuring the protein synthesis. The ricin-induced and the
CHX-induced inhibition on protein synthesis, 70% and 35%
reduction, respectively, were not affected by the addition of
serum (Figure 5D).
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Figure 4 Survival curves (A) of nude rats injected with HeLa* cells in left
cardiac ventricle (LV). Nude rats were treated with IT and/or CsA or
control vehicle (PBS) in a volume of 100ml. CsA (10mgkg
 1 per day) was
given every day for 5 days starting on day 0 (cell injection, 1 10
6 cells),
and BM7PE (10mg) was given as a single dose on day 1 after tumour cell
injection. (B) A statistically significant prolongation in survival (P¼0.022) of
rats in the IT and CsA combination-treated group compared with mono-IT
therapy. The results were calculated by the all pair-wise multiple
comparison procedure by the Holm–Sidak method. (C) The combination
of IT MOC31PE and CsA increased survival of nude rats injected with
MA11 cells in LV. The rats were treated with a single injection of IT
MOC31PE (10mg) and/or CsA as outlined in (A).
aILS, increase in lifespan
(median survival time-treated group/median survival time control group 1)
 100%. Survivors (survivors/total number of animal per group).
bFollow-
up period 490 days. CsA (CsA, sandimmun, Novartis).
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Figure 5 Immunotoxin (IT)-induced antibody generation in immunocompetent rats was suppressed by CsA. The upper part of the (A) shows the
scheduling of the treatment. Treatment with MOC31PE leads to the development of anti-IT IgG in immunocompetent rats, as analysed by ELISA (A, lower
part). The table shows the anti-IT IgG levels in the rat sera. Day 0 (column 1) blood was collected from all animals and analysed as a zero reference of anti-IT
IgG. The rats in groups C and D were treated with CsA only, 10mgkg
 1 per day for 5 days (days 0–4). On day 1 the animals in group B and C were
injected i.v. with MOC31PE (100mgkg
 1). Treatment repeated as outlined every second week, for a total of 8 weeks, induced a massive generation of anti-
IT IgG in group B, which was completely prevented in rats given MOC31PE and CsA (group C). The untreated and CsA groups (A and D) did not develop
antibodies. n¼10 per group for the IT and ITþCsA groups, and n¼7 for the control (vehicle) and CsA alone groups. (B) Serum from IT-treated
immunocompetent rats inhibited the Pseudomonas Exotoxin A (PE)-induced cytotoxicity. Glioblastoma cells U251MG with a high expression of PE
receptors (a-macroglobulin receptor) were incubated with PE (1000ngml
 1) with or without the presence of 2.5% serum from the treated rats, groups
A–D column 5, or fetal calf serum (FCS) for 24h before the MTS assay was performed. The data are expressed as the mean of triplicates, representative of
two independent experiments and representative of sera from five animals per treatment group. (C) Serum from IT-treated animals blocked PE-induced
inhibition of protein synthesis. Glioblastoma cells U251MG were incubated with PE (1000ngml
 1) with or without the presence of serum (0.025% or 0.25%
or 2.5%) from the IT-treated animals (group B column 5) for 24h before the protein synthesis assay was performed. The data are expressed as the mean of
triplicates, representative of two independent experiments. The experiment was repeated with four different IT-treated animal sera showing similar results.
(D) Serum from IT-treated immunocompetent rats did not block the effects of other protein synthesis inhibitors. Glioblastoma cells U251MG were
incubated with ricin (1mM) and cycloheximide (CHX) (5mgml
 1) with or without the presence of serum (2.5%) from the IT-treated animals (group B
column 5) for 24h before the protein synthesis assay was performed. The data are expressed as the mean of triplicates, representative of two independent
experiments. The experiment was repeated with two different IT-treated animals serum (group B column 5) showing similar results.
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the specific anti-IT response generated in IT-treated animals by
including CsA.
DISCUSSION
Previously, we have studied the anti-cancer properties and
intracellular mechanisms involved in 425.3PE-induced effects
in vitro in the human breast cancer cell line MA11 (Andersson
et al, 2004, 2006). The aim of this study was to further improve
the efficacy of ITs and attempt to minimise the immunogenic
antibody response to ITs, a major challenge to the in vivo use of
ITs as they prevent the effect of repeated administration. CsA was
chosen as a known potent and clinically important immuno-
suppressive agent.
In the experiments in MA11 cells, the combination of IT and
CsA acted synergistically on protein synthesis inhibition and
on cell death with increased induction of apoptosis. The DNA
fragmented fraction increased more than 10-fold when a low
dose of IT (0.1ngml
 1), not able to induce DNA fragmentation
by itself, was combined with CsA. The data show that a close
to non-cytotoxic IT dose became clearly cytotoxic when used in
combination with CsA.
Similar to CsA, the two immunosuppressive drugs, tacrolimus
and sirolimus (rapamycin), are used clinically to prevent
immunologic rejection after solid-organ transplantation. Our
findings indicate that despite the similar mechanistic effects of
these immunosupressor, only CsA had the ability to synergistically
increase the cytotoxicity of IT in vitro. This difference might be
explained by the fact that the drugs have different cellular targets
(Arceci et al, 1992; Weischer et al, 2007).
The ITþCsA combination was examined in a number of cell
lines of different cancer types: cervical HeLa*, breast T47D and
MA11, prostate DU145, glioblastoma D54MG (all with mutated
p53), and glioblastoma U87MG (with wild-type p53). Our findings
clearly indicate that cancer cells mutated in p53 are, independent
of cancer origin, likely to be sensitive to the combination of IT and
CsA. TP53 is mutated in B50% of human cancers (Soussi and
Wiman, 2007), and our findings are important as TP53-mutated
tumours are commonly resistant to radiation and to the majority
of anticancer drugs used in the clinic. Notably, the synergistic
increase in IT cytotoxicity by CsA was independent of the cellular
target (EGFr, EGP2, and mucin-1).
The mechanisms and the factors responsible for the synergistic
effects have not yet been fully elucidated. However, one likely
explanation is a direct triggering of apoptosis illustrated by
increased PARP inactivation and DNA fragmentation, rather than
interference with cell-cycle events as the distribution of the cells
in different cell-cycle phases was not changed (data not shown).
The explanation for the increased fraction of positive TUNEL-
stained cells induced by CsA alone might be related to the CsA
inhibitory effect on calcineurin (protein phospatase 2B), a factor
known to be involved in reduced DNA repair (Weischer et al,
2007). In our experiments, CsA alone (0.1–2mM for 5 or 24h
depending on cell line) caused no PARP inactivation. Importantly,
several in vitro studies have shown that CsA alone can induce
apoptosis (PARP inactivation) although at much higher concen-
trations (30–60mM) (Pyrzynska et al, 2002; Ciechomska et al,
2005). The in vitro data on the combination of IT and CsA
encouraged us to examine the effects in vivo. In a HeLa* cervical
cancer model and a MA11 breast cancer model in nude rats
administration of a suboptimal dose of BM7PE and MOC31PE,
respectively, and used in combination with CsA did reduce the
metastatic capacity of the HeLa* cells and MA11 cells and
prolonged the survival time of the animals compared with IT
alone. The HeLa* cells metastasize with a shorter lag period than
the MA11 cells even with a lower number cells injected, as also
reported earlier (Engebraaten and Fodstad, 1999). Notably, in
the MA11 tumour model, the fraction of surviving animals
compared with untreated animals was much larger in the ITþCsA
group (33%, n¼12) compared with IT group (10%, n¼10),
whereas the increase in lifespan of rats developing metastases
was the same for both groups, 170% compared with untreated
control animals. Recently, it was shown that CsA could inhibit
intracranial glioma growth in vivo (Sliwa et al, 2007) most
likely because of an inhibition of the PI-3/Akt pathway
(Ciechomska et al, 2003). In our models, CsA alone had no effect
on metastasis development. Moreover, the fact that the observed
synergistic effect was shown in an immune-deficient nude rat
model indicates that the pro-apoptotic combination effect of IT
and CsA in vitro and in vivo is not linked to the immunosup-
pressive activity of CsA.
Notably, in immunocompetent rats, the combination with CsA
mediated an efficient block of the anti-IT antibody response, which
otherwise impedes effective IT therapy. The treatment schedule of
IT in these animals was translated from the ongoing phase I study
of IT alone at The Norwegian Radium Hospital (unpublished) in
which IT is given every second week and repeated four times.
In the IT-treated group of animals, the level of anti-IT antibodies
was already high after only two IT injections and increased further
during the treatment period, corresponding to the levels of
anti-IT antibodies found in the clinical phase I study (unpublished
results). Serum from the animals strongly neutralised the
cytotoxicity of PE or IT in an in vitro cell cytotoxic MTS
assay. Importantly, when CsA was administrated together with
IT no anti-IT antibody development was seen, as demonstrated
by both ELISA and in the cytotoxic MTS assay. The data imply
that the use of a combination of IT and CsA in the clinic
has a promising potential. CsA has been previously shown
to enable repeated administration of monoclonal antibody therapy
in patients by reducing the HAMA response (Ledermann
et al, 1988; Weiden et al, 1994). Notably, the amount of CsA
administered in the in vivo experiments in rats was lower,
based on several publications (Palomero et al, 2001; Lee et al,
2002), that the doses commonly used in patients for immuno-
supression, as calculated from commonly used guidelines for
conversion of doses between different species (www.fda.gov/Cber/
gdlns/dose.htm). However, whether CsA can inhibit the antibody
formation to the IT will be studied in a clinical trial in 2009 in our
clinical trials unit.
In earlier clinical trials with ITs, the patients have aquired VLS,
linked to a damage in the capillary vessel wall probably caused by
(IT damage or) specific but unwanted binding of the antibody to
the endothelial cells. The VLS has never occurred in our preclinical
animal models (own data, unpublished).
Critical concerns of using fully PE linked to fully mouse
antibody have been raised, and on this background modified
PE-containing ITs have been preferred for clinical trials. However,
clinical beneficial effects have not been obtained, possibly
related to pharmacokinetic and scheduling factors. We have
documented in a phase I study a safe administration of the
full IT, which can easily be produced in the necessary amounts
for clinical use. Owing to the size of the full IT molecule the
most advantageous clinical setting for our approach would be
patients with minimal residual disease, for example adjuvant
therapy.
Critical concerns of long-term CsA usage in transplanted
patients have been raised, as one serious potential side effect is
an increase risk for certain cancers. However, other and contra-
dictory results show that CsA might have a positive function in
cancer prevention (Weischer et al, 2007). According to medical
data bases, a daily CsA dose (3–7mgkg
 1) was used in several
clinical studies for months without any significant side effects
including cancer (Frei et al, 1998; Koo, 1998; Levy et al, 2002;
Vakeva et al, 2008). Importantly, IT combination therapy with CsA
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in clinic, for example, CsA for 5 days and 9 days off and then the
same schedule repeated for six more weeks.
In summary, we have shown a novel and effective anti-cancer
combination therapy with IT and CsA both in vitro and in nude
rats. The combination therapy might facilitate the use of IT in
clinic, as the combination simultaneously increased the anti-
cancer activity of IT and efficiently inhibited the generation of
neutralising anti-IT antibodies, which has been preventing
effective prolonged IT therapy.
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